Emmaus Life Sciences Announces Update of its Partnership with taiba Healthcare to Expand Patient Access for Sickle Cell Disease Treatment in the Middle East and North Africa (MENA) Region

Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, today reported that it expects to receive shortly the initial purchase orders relating to taiba Healthcare's early access program for Endari® (L-glutamine oral powder) in certain countries in  the Middle East and North Africa (MENA) region. The MENA region represents a substantially larger market for Endari than the United States with Saudi Arabia alone having more patients afflicted with sickle cell disease than in the U.S.

"Our team has received positive feedback from HCPs across the territory who are excited to have L-glutamine as a valuable therapeutic option for the treatment of sickle cell disease patients," said Dr. Saif Al-Hasani, Chief Executive Officer of taiba. Dr. Saif Al-Hasani added, "We expect within the first quarter of 2020 to have received requests for early access programs from the Gulf Cooperation Countries as the start of providing access to this valuable treatment for a significant number of sickle cell disease patients in our region."

"In a relatively short period of time, taiba has become a valuable partner in bringing patients in the Middle East this much needed drug. Through this partnership, we have already identified 40 patients and look forward to working with taiba to expand and increase access to patients in the entire MENA region," said George Sekulich, Senior Vice President of Global Commercialization for Emmaus Life Sciences.

Dr. Yutaka Niihara, M.D., M.P.H., Chairman and Chief Executive Officer of Emmaus added, "We are grateful to have taiba as our partner in the very important MENA region and greatly appreciate their support and commitment in helping us improve the lives of sickle cell disease patients by providing early access to our efficacious and safe treatment."

About Emmaus Life Sciences 
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories. 

About Endari® (L-glutamine oral powder)
Indication - Endari is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.

Important Safety Information - The most common adverse reactions (incidence >10 percent) in clinical studies were constipation, nausea, headache, abdominal pain, cough, pain in extremities, back pain, and chest pain.

Adverse reactions leading to treatment discontinuation included one case each of hypersplenism, abdominal pain, dyspepsia, burning sensation, and hot flash.

The safety and efficacy of Endari in pediatric patients with sickle cell disease younger than five years of age has not been established.

Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,
for any copyright disputes involved in the reproduced articles,
please email: Julia.Zhang@ubmsinoexpo.com to motify or remove the content.